Trojan Bio

Company Overview

Snapshot

Founded in October 2021 by Anat Burkovitz, Amir Aharoni, and Noam Diamant, Trojan Bio operates with 1–10 employees. The company has secured funding across two rounds. In December 2023, Trojan Bio received a Seed round of funding, advancing its preclinical immunotherapy efforts.

Business overview

Trojan Bio is a preclinical immunotherapy company focused on developing a new class of therapeutic antibodies for various cancers. The company's core technology involves 'Trojan antibodies' that integrate viral peptides to activate the immune system, effectively labeling cancer cells as virally infected to harness anti-viral immunity for cancer eradication. Trojan Bio operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development industries, with a focus on pharmaceutical customers.

Company Intelligence Q&A

What is Trojan Bio's primary focus?

Trojan Bio is a preclinical immunotherapy company developing a novel class of therapeutic antibodies for the treatment of various cancers.

When was Trojan Bio founded and by whom?

Trojan Bio was founded in October 2021 by Anat Burkovitz, Amir Aharoni, and Noam Diamant.

Which investors have participated in Trojan Bio's funding rounds?

Trojan Bio has received funding from investors including Peregrine Ventures.

What is the core technology behind Trojan Bio's approach?

Trojan Bio's core technology involves 'Trojan antibodies' that integrate viral peptides to activate the immune system, labeling cancer cells as virally infected to leverage anti-viral immunity.

What was Trojan Bio's most recent funding event?

In December 2023, Trojan Bio secured a Seed funding round from Peregrine Ventures.